ArticleEmerging infectious diseases2025
Macrolide-Resistant Mycoplasma pneumoniae in Children, Ohio, USA.
Article in Emerging infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Genomic Surveillance Reveals Emergence and Spread of Macrolide-Resistant Mycoplasma pneumoniae in Australia During the 2023-2024 Epidemic.The Journal of infectious diseases · 2026Article
- Post-pandemic surge ofJournal of clinical microbiology · 2026Article
- The Post-Pandemic Return ofJournal of clinical medicine · 2026Article
- Population structure reveals clade- and region-specific dissemination of macrolide-resistantFrontiers in cellular and infection microbiology · 2026Article
- Macrolide Resistance ofInfection and drug resistance · 2026Article
- A Case of Macrolide-Resistant Mycoplasma Pneumonia Developing Shortly After Macrolide-Susceptible Infection.Pediatrics international : official journal of the Japan Pediatric SocietyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As the COVID-19 pandemic waned, Mycoplasma pneumoniae reemerged in the pediatric population in Ohio, USA. The rate of macrolide-resistant M. pneumoniae fluctuated by month, ranging from 0 to 8.7%, and mirrored the azithromycin prescribing rate. Real-time surveillance for macrolide-resistant M. pneumoniae provides accurate information for management of children with these infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.